Similar articles for PMID: 29628508

Year	Number of Results
2000	2
2003	1
2004	1
2007	1
2008	2
2009	1
2010	1
2011	3
2013	2
2014	1
2015	8
2016	11
2017	10
2018	12
2019	17
2020	18
2021	15
2022	5
2023	3
2024	0

1

A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma.

Labgaa I, Villacorta-Martin C, D'Avola D, Craig AJ, von Felden J, Martins-Filho SN, Sia D, Stueck A, Ward SC, Fiel MI, Mahajan M, Tabrizian P, Thung SN, Ang C, Friedman SL, Llovet JM, Schwartz M, Villanueva A. Labgaa I, et al. Oncogene. 2018 Jul;37(27):3740-3752. doi: 10.1038/s41388-018-0206-3. Epub 2018 Apr 9. Oncogene. 2018. PMID: 29628508 Free PMC article.

2

Genetic profiling using plasma-derived cell-free DNA in therapy-naïve hepatocellular carcinoma patients: a pilot study.

Ng CKY, Di Costanzo GG, Tosti N, Paradiso V, Coto-Llerena M, Roscigno G, Perrina V, Quintavalle C, Boldanova T, Wieland S, Marino-Marsilia G, Lanzafame M, Quagliata L, Condorelli G, Matter MS, Tortora R, Heim MH, Terracciano LM, Piscuoglio S. Ng CKY, et al. Ann Oncol. 2018 May 1;29(5):1286-1291. doi: 10.1093/annonc/mdy083. Ann Oncol. 2018. PMID: 29509837 Free article.

3

Targeted Next-Generation Sequencing Combined With Circulating-Free DNA Deciphers Spatial Heterogeneity of Resected Multifocal Hepatocellular Carcinoma.

Lin J, Zhao S, Wang D, Song Y, Che Y, Yang X, Mao J, Xie F, Long J, Bai Y, Yang X, Zhang L, Bian J, Lu X, Sang X, Pan J, Wang K, Zhao H. Lin J, et al. Front Immunol. 2021 Jun 15;12:673248. doi: 10.3389/fimmu.2021.673248. eCollection 2021. Front Immunol. 2021. PMID: 34211467 Free PMC article.

4

Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing.

Liao W, Yang H, Xu H, Wang Y, Ge P, Ren J, Xu W, Lu X, Sang X, Zhong S, Zhang H, Mao Y. Liao W, et al. Oncotarget. 2016 Jun 28;7(26):40481-40490. doi: 10.18632/oncotarget.9629. Oncotarget. 2016. PMID: 27248174 Free PMC article.

5

Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma.

Howell J, Atkinson SR, Pinato DJ, Knapp S, Ward C, Minisini R, Burlone ME, Leutner M, Pirisi M, Büttner R, Khan SA, Thursz M, Odenthal M, Sharma R. Howell J, et al. Eur J Cancer. 2019 Jul;116:56-66. doi: 10.1016/j.ejca.2019.04.014. Epub 2019 Jun 4. Eur J Cancer. 2019. PMID: 31173963 Free article.

6

Personalized circulating tumor DNA in patients with hepatocellular carcinoma: a pilot study.

Pommergaard HC, Yde CW, Ahlborn LB, Andersen CL, Henriksen TV, Hasselby JP, Rostved AA, Sørensen CL, Rohrberg KS, Nielsen FC, Rasmussen A. Pommergaard HC, et al. Mol Biol Rep. 2022 Feb;49(2):1609-1616. doi: 10.1007/s11033-021-06962-1. Epub 2021 Nov 22. Mol Biol Rep. 2022. PMID: 34811635

7

Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma.

von Felden J, Craig AJ, Garcia-Lezana T, Labgaa I, Haber PK, D'Avola D, Asgharpour A, Dieterich D, Bonaccorso A, Torres-Martin M, Sia D, Sung MW, Tabrizian P, Schwartz M, Llovet JM, Villanueva A. von Felden J, et al. Oncogene. 2021 Jan;40(1):140-151. doi: 10.1038/s41388-020-01519-1. Epub 2020 Oct 23. Oncogene. 2021. PMID: 33097857

8

TP53 Targeted Deep Sequencing of Cell-Free DNA in Esophageal Squamous Cell Carcinoma Using Low-Quality Serum: Concordance with Tumor Mutation.

Nasrollahzadeh D, Roshandel G, Delhomme TM, Avogbe PH, Foll M, Saidi F, Poustchi H, Sotoudeh M, Malekzadeh R, Brennan P, Mckay J, Hainaut P, Abedi-Ardekani B. Nasrollahzadeh D, et al. Int J Mol Sci. 2021 May 26;22(11):5627. doi: 10.3390/ijms22115627. Int J Mol Sci. 2021. PMID: 34073316 Free PMC article.

9

TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma.

Ye S, Zhao XY, Hu XG, Li T, Xu QR, Yang HM, Huang DS, Yang L. Ye S, et al. Oncol Rep. 2017 Apr;37(4):2215-2226. doi: 10.3892/or.2017.5494. Epub 2017 Mar 8. Oncol Rep. 2017. PMID: 28350084 Free PMC article.

10

Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics.

Ikeda S, Lim JS, Kurzrock R. Ikeda S, et al. Mol Cancer Ther. 2018 May;17(5):1114-1122. doi: 10.1158/1535-7163.MCT-17-0604. Epub 2018 Feb 26. Mol Cancer Ther. 2018. PMID: 29483209 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year